Treatment of chronic hepatitis C (HCV) has rapidly evolved from modestly-effective interferon-based regimens to highly effective, all oral, interferon-free directly acting antiviral (DAA) therapy. While DAAs are increasingly used for treatment of HCV worldwide, the impact of emerging resistance is largely unknown. In this study, we evaluated the role of baseline, treatment-emergent and treatment-enriched resistance associated variants of HCV on sustained virologic response (SVR) at initial, short-duration, all oral DAA treatment and at re-treatment with a second DAA only regimen for patients who failed initial therapy.
NIAID SYNERGY is an innovative 8 arm clinical trial that treated over 200 hepatitis C patients with varying sofosbuvir(SOF)-based DAA regimens (Figure 1). Deep sequencing was performed on plasma at baseline on all patients, at the time of relapse in patients failing therapy, and prior to retreatment, when appropriate. RAVS were classified as baseline, treatment-enriched (those increasing in proportion to wild type from baseline to relapse) and treatment-emergent (those which were not present at baseline). Correlation analysis was performed between RAVs and sustained virologic response (SVR).
For treatment naïve patients, pre-treatment RAVs did not predict SVR in patients who received at least 6 weeks of DAA therapy (SYNERGY A, B, C, E, F). Similarly, no association was observed between baseline RAVs and SVR among treatment-experienced patients and those with advanced liver fibrosis (SYNERGY F) treated for 6 weeks (P=0.69). For patients receiving ultra short duration therapy (4 weeks), regardless of liver fibrosis, high level RAVs (conferring > 20 fold resistance) present prior to treatment were associated with relapse (SYNERGY G/H, P=0.03). However, when these relapsed patients were retreated with SOF and ledipasvir (LDV) for 12 weeks (85% of those previously treated with LDV/SOF had high level NS5A RAVs prior to retreatment), 91% achieved SVR (SYNERGY D).
HCV NS5A RAVs do not predict relapse when using sofosbuvir-based treatment for at least 6 weeks or during re-treatment with standard 12 week regimens of LDV/SOF. RAVs do appear to impact treatment response when treating with ultra-short, 4 week duration therapies.